Isolation of commensal N-acyl amides
To identify N-acyl synthase (NAS) genes within human microbial genomes, the Human Microbiome Project (HMP) sequence data was searched with BLASTN using 689 NAS genes associated with the N-acyl synthase protein family PFAM13444 (ref. 3) . The 143 unique human microbial (hm) N-acyl synthase genes (hm-NAS genes), which we identified, fall into four major clades (clades A-D, Fig. 1a ) that are divided into a number of distinct sub-clades ( Fig. 1a ). Forty-four phylogenetically diverse hm-NAS genes were selected for synthesis and heterologous expression. This set included all hm-NAS genes from clades sparsely populated with hm-NAS sequences and representative examples from clades heavily populated with hm-NAS sequences (Fig. 1a) .
Liquid chromatography-mass spectrometry (LC-MS) analysis of ethyl acetate extracts derived from Escherichia coli cultures transformed with each construct revealed clone-specific peaks in 31 cultures. hm-NAS gene functions could be clustered into six groups based on the retention time and mass of the heterologously produced metabolites (Extended Data Fig. 1 and Supplementary Table 1 ). Molecule isolation and structural elucidation studies were carried out on one representative culture from each group (Supplementary Information). This analysis identified six N-acyl amide families that differ by amine head group and fatty acid tail ( Fig. 1b , families 1-6):
(1) N-acyl glycine; (2) N-acyloxyacyl lysine; (3) N-acyloxyacyl glutamine; (4) N-acyl lysine/ornithine; (5) N-acyl alanine; (6) N-acyl serinol. Each family was isolated as a collection of metabolites with different acyl substituents. The most common analogue within each family is shown in Fig. 1b . Long-chain N-acyl ornithines, lysines and glutamines have been reported as natural products produced by soil bacteria and some human pathogens [6] [7] [8] .
Commensal bacteria are believed to have important roles in human health. The mechanisms by which they affect mammalian physiology remain poorly understood, but bacterial metabolites are likely to be key components of host interactions. Here we use bioinformatics and synthetic biology to mine the human microbiota for N-acyl amides that interact with G-protein-coupled receptors (GPCRs). We found that N-acyl amide synthase genes are enriched in gastrointestinal bacteria and the lipids that they encode interact with GPCRs that regulate gastrointestinal tract physiology. Mouse and cell-based models demonstrate that commensal GPR119 agonists regulate metabolic hormones and glucose homeostasis as efficiently as human ligands, although future studies are needed to define their potential physiological role in humans. Our results suggest that chemical mimicry of eukaryotic signalling molecules may be common among commensal bacteria and that manipulation of microbiota genes encoding metabolites that elicit host cellular responses represents a possible small-molecule therapeutic modality (microbiome-biosynthetic gene therapy).
Functional differences in NAS enzymes follow the pattern of the NAS phylogenetic tree, with hm-NAS genes from the same clade or sub-clade mostly encoding the same metabolite family ( Fig. 1a ).
With the exception of one NAS that is predicted to use lysine and ornithine as substrates, hm-NAS proteins appear to be selective for a single amine-containing substrate. The most common acyl chains incorporated by hm-NAS proteins are 14-18 carbons in length. These can be modified by β -hydroxylation or a single unsaturation. Three hm-NAS enzymes contain two domains. The second domain is either an aminotransferase that is predicted to catalyse the formation of serinol from glycerol ( Fig. 1b , family 6 and Extended Data Fig. 2) or an additional acyltransferase that is predicted to catalyse the transfer of a second acyl group (Fig. 1b , families 2 and 3). To explore NAS gene synteny, we looked for gene occurrence patterns around NAS genes in the human microbiome. The only repeating pattern that we saw was that some NAS genes appear adjacent to genes predicted to encode acyltransferases. This is reminiscent of the two domain NAS proteins that we found produce di-acyl metabolites (families 2 and 3). There were rare instances where NAS proteins potentially occur in gene clusters, but none of these were used in this study.
To look for native N-acyl amide production by commensal bacteria, organic extracts from cultures of species containing the hm-NAS genes that we examined were screened by LC-MS. On the basis of retention time and mass, we detected the production of the expected N-acyl amides by commensal species predicted to produce N-acyl glycines, N-acyloxyacyl lysines, N-acyl lysine/ornithines and N-acyl serinols. The only case where we did not detect the expected N-acyl amide was for N-acyloxyacyl glutamines (Extended Data Fig. 1 ).
hm-NAS genes are enriched in gastrointestinal bacteria
A BLASTN search of NAS genes against human microbial reference genomes and metagenomic sequencing data from the HMP showed that NAS genes were enriched in gastrointestinal bacteria relative to bacteria found at other body sites (Fisher's exact test P < 0.05, gastrointestinal versus non-gastrointestinal sites; Fig. 1 and Supplementary  Table 2 ). Within gastrointestinal sites that were frequently sampled in the context of the HMP (for example, stool, buccal mucosa, supragingival plaque and tongue) hm-NAS gene families show distinct distribution patterns ( Fig. 1c , two-way ANOVA P < 2 × 10 −16 ). Despite very large person-to-person variation in microbiota species composition, most of the N-acyl amide synthase gene families that we studied can be found in over 90% of patient samples. N-acyoxyacyl glutamine (12%) and N-acyl alanine (not detected) synthase genes are the only exceptions. Taken together, these data suggest that NAS genes are highly prevalent in the human microbiome and unique sites within the gastrointestinal tract are probably exposed to different sets of N-acyl amide structures.
When we searched existing metatranscriptome sequence data from stool and supragingival plaque microbiomes to look for evidence of Figure 1 | hm-NAS genes in gastrointestinal microbiota. a, Phylogenetic tree of N-acyl genes from PFAM13444. hm-NAS genes have a dot at the branch tip. Black dots were not synthesized, red dots were synthesized, but no molecule was detected and large grey dots mark genes that produced N-acyl amides. Branches are coloured by bacterial phylogeny. b, The major heterologously produced metabolite from each N-acyl family (1) (2) (3) (4) (5) (6) is shown. c, hm-NAS gene distribution and abundance (reads per kilobase of gene per million reads (RPKM)) based on molecule family (1) (2) (3) (4) (5) (6) . Body site and molecule designations in a are based on the analysis shown in c and b. Box plots are median and 1st to 3rd quartile. HMP patient samples analysed include n = 133 tongue, 127 plaque, 148 stool, 122 buccal samples. hm-NAS gene expression in the gastrointestinal tract, we observed site-specific hm-NAS gene expression that matches the predicted body site localization patterns for hm-NAS genes in metagenomic data. Across patient samples, hm-NAS genes are transcribed to varying degrees relative to the average level of transcription for each gene in the bacterial genome ( Fig. 2a ). In the stool metatranscriptome dataset, both RNA and DNA sequencing datasets were available allowing a more direct sample-to-sample comparison of hm-NAS gene expression levels. When metatranscriptome data were normalized using the number of hm-NAS gene-specific DNA sequence reads detected in each sample, we observed what appears to be differential expression of hm-NAS genes in different patient samples ( Fig. 2b ). Datasets for which bacterial genes, transcripts and metabolites can be tracked in a single sample will be necessary to explore how hm-NAS gene transcription variation affects metabolite production.
N-acyl-amides interact with gastrointestinal GPCRs
The major N-acyl amide isolated from each family was assayed for agonist and antagonist activity against 240 human GPCRs ( Fig. 3 and Extended Data Fig. 3 ). The strongest agonist interactions were: activation of GPR119 by N-palmitoyl serinol (half maximal effective concentration (EC 50 ) = 9 μ M), activation of sphingosine-1-phosphate receptor 4 (S1PR4) by N-3-hydroxypalmitoyl ornithine (EC 50 = 32 μ M) and activation of G2A by N-myristoyl alanine (EC 50 = 3 μ M). Interactions between bacterial N-acyl amides and GPCRs were also specific ( Fig. 3a, b ). In each experiment, no other GPCRs reproducibly showed greater than 35% activation relative to the endogenous ligands. The strongest antagonist activities were observed for N-acyloxyacyl glutamine against two prostaglandin receptors, PTGIR and PTGER4 ( Fig. 3c ; PTGIR, half maximal inhibitory concentration (IC 50 ) = 15 μ M; PTGER4, IC 50 = 43 μ M). PTGIR was specifically antagonized by N-acyloxyacyl glutamine, whereas PTGER4 was antagonized by N-acyloxyacyl glutamine as well as other N-acyl amides ( Fig. 3c ). Alternative GPCR screening methods could identify interactions in addition to those uncovered here.
On the basis of data from the Human Protein Atlas, GPCRs targeted by human microbial N-acyl amides are localized to the gastrointestinal tract and its associated immune cells. In mouse models, this collection of GPCRs have been reported to affect diverse mucosal functions, including metabolism (GPR119), immune cell differentiation (S1PR4, PTGIR and PTGER4), immune cell trafficking (S1PR4, G2A) and tissue repair (PTGIR) [9] [10] [11] [12] [13] [14] . It is not possible at this time to look for co-localization of GPCR and hm-NAS gene expression in specific gastrointestinal niches, as neither the HMP nor the Human Protein Atlas are sufficiently comprehensive in their survey of human body sites. Nonetheless, 16S and metagenomic deep-sequencing studies link bacteria containing hm-NAS genes or hm-NAS genes themselves to specific locations in the gastrointestinal tract where the GPCRs of interest are expressed (Extended Data Fig. 4 ).
Similarity of bacterial and human GPCR ligands
Human microbiota-encoded N-acyl amides bear structural similarity to endogenous GPCR-active ligands (Fig. 4 ). The clearest overlap in structure and function between bacterial and human GPCR-active ligands is for the endocannabinoid receptor GPR119 (Figs 4, 5) . Endogenous GPR119 ligands include oleoylethanolamide (OEA) and the dietary lipid-derivative 2-oleoyl glycerol (2-OG) 15, 16 . In our heterologous expression experiment, we isolated both the palmitoyl and oleoyl analogues of N-acyl serinol. The latter only differs from 2-OG by the presence of an amide instead of an ester and from OEA by the presence of an additional methanol substituent. N-oleoyl serinol is a similarly potent GPR119 agonist as the endogenous ligand OEA (EC 50 = 12 μ M versus 7 μ M), but elicits an almost twofold greater maximum GPR119 activation ( Fig. 5a ). N-palmitoyl derivatives of all 20 natural amino acids were synthesized and none activated GPR119 by more than 37% relative to OEA (Fig. 5b) . The generation of a potent and specific long-chain N-acyl-based GPR119 ligand therefore necessitates a more complex biosynthesis than the simple N-acylation of an amino acid, as is commonly seen for characterized NAS enzymes. In this case, the biosynthesis of N-acyl serinols is achieved through the coupling of an NAS domain with an aminotransferase that is predicted to generate serinol from glycerol (Extended Data Fig. 2 ). The endogenous agonist for S1PR4, sphingosine-1-phosphate (S1P) and the N-3-hydroxypalmitoyl ornithine/lysine family of bacterial agonists share similar head group charges. S1P is a markedly more potent agonist (EC 50 = 0.09 μ M versus EC 50 = 32 μ M); however, the bacterial agonists are more specific for S1PR4. The bacterial N-3hydroxypalmitoyl ornithine did not activate S1PR1, 2 or 3 in our GPCR screen, whereas S1P activates all four members of the S1P receptor family that were tested.
No direct comparison could be made between the microbiotaderived and endogenous ligands for PTGIR or PTGER4, because there are no known endogenous antagonists for these receptors. Many human GPCRs remain orphan receptors lacking known endogenous ligands. Ligands for at least some of these receptors will undoubtedly be found among the small molecules produced by the human microbiota. G2A is an orphan receptor and therefore does not have a well-defined endogenous agonist, although it has been reported to respond to lysophosphatidylcholine 17, 18 . We found that the bacterial metabolites N-3-hydroxypalmitoyl glycine (commendamide) and N-palmitoyl alanine both activate G2A. Mammals produce N-palmitoyl glycine, which differs from commendamide by the absence of the β -hydroxyl and which activates G2A, based on our synthetic N-acyl studies 19 .
GPR119 is the most extensively studied of the GPCRs activated by bacterial ligands we identified ( Fig. 4 ). Mechanisms that link endogenous GPR119 agonists (OEA, 2-OG) to changes in host phenotype are well-defined as a result of the exploration of GPR119 as a therapeutic target for diabetes and obesity [20] [21] [22] [23] . GPR119 agonists are thought not only to primarily affect glucose homeostasis, but also gastric emptying and appetite through both GPR119-dependent hormone release from enteroendocrine (GLP-1, GIP, PYY) and pancreatic β-cells (insulin) as well as GPR119-independent mechanisms, including PPARα modulation 9, 16, [24] [25] [26] [27] [28] [29] [30] . Mouse enteroendocrine GLUTag cells have been used as a model system for measuring the ability of potential GPR119 agonists to induce GLP-1 release. When administered to GLUTag cells at equimolar concentrations, microbiota-encoded N-oleoyl serinol or the endogenous ligands OEA and 2-OG induced GLP-1 secretion to the same magnitude ( Fig. 5c ). To provide an orthogonal measurement of GPR119 activation by N-acyl serinols, HEK293 cells were stably transfected with a GPR119 expression construct. Both OEA and N-oleoyl serinol increased cellular cAMP concentrations in a GPR119-dependent manner (Extended Data Fig. 5 ).
hm-NAS expression alters blood glucose in mice
The functional overlap between endogenous and bacterial metabolites suggested that bacteria expressing microbiota-encoded GPR119 ligands might elicit host phenotypes that mimic those induced by eukaryotic ligands. Endogenous and synthetic GPR119 ligands have been associated with changes in glucose homeostasis that are relevant to the aetiology and treatment of diabetes and obesity, including a study where mice were orally administered bacteria that had been engineered to produce a eukaryotic enzyme that increases endogenous GPR119 ligand (OEA) precursors 9, 16, [24] [25] [26] [27] 31 . The metabolic effect of the endogenous GPR119 ligands is believed to occur at the intestinal mucosa, because the delivery of OEA intravenously fails to lower blood glucose in mice during an oral glucose-tolerance test (OGTT) 26 . Consequently, we sought to determine whether mice colonized with bacteria that had been engineered to produce N-acyl serinols would exhibit predictable host phenotypes. Gnotobiotic mice were colonized with E. coli engineered to express the N-acyl serinol synthase gene in an isopropylβ -d-thiogalactoside (IPTG)-dependent manner. Control mice were colonized with E. coli expressing an empty vector. On the basis of the number of colony-forming units detected in faecal pellets, both cohorts of mice were colonized to the same extent (Extended Data Fig. 7 ). After one week of exposure to IPTG, both cohorts were fasted overnight and subjected to an OGTT. At 30 min after the challenge, we observed a statistically significant decrease in blood glucose levels for the group colonized with E. coli expressing the N-acyl serinol synthase gene ( Fig. 5d ). Mass spectrometry analysis of metabolites present in caecal samples revealed the presence of N-acyl serinols in the treatment cohort, but not in the control cohort (Extended Data Fig. 6 ). After two weeks of withdrawing IPTG from the drinking water, we no longer observed a difference in blood glucose between the two cohorts after an OGTT 32 (Fig. 5e ).
To further explore the metabolic phenotype induced by N-acyl serinols we repeated the OGTT experiment in an antibiotic-treated mouse model. In this study, we compared mice colonized with E. coli expressing an active N-acyl serinol synthase to mice colonized with E. coli expressing an NAS point mutant (p.Glu91Ala; Extended Data Fig. 8 ) that no longer produced N-acyl serinols. In this model, the glucose lowering effect of colonization with N-acyl serinol-producing E. coli remained significant (Fig. 5f ). In the antibiotic-treated mice, we measured GLP-1 and insulin concentrations after glucose gavage. Both hormones were significantly increased in the treatment group compared to the control group (Fig. 5g, h) . In all mouse models, the observed correlation between hm-NAS gene induction and increased glucose tolerance is similar in magnitude to several studies with small-molecule GPR119 agonists including glyburide, an FDAapproved therapeutic for diabetes 24, 25 .
Discussion
Our characterization of human microbial N-acyl amides, together with other investigations of the human microbiota, suggests that host-microbial interactions may rely heavily on simple metabolites built from the same common lipids, sugars and peptides that define many human signalling systems (for example, neurotransmitters, bioactive lipids and glycans). This is not surprising as the genomes of the bacterial taxa common to the human gastrointestinal tract (for example, Bacteroidetes, Firmicutes and Proteobacteria) are often lacking in gene clusters that encode the production of complex secondary metabolites (for example, polyketides, non-ribosomal peptides and terpenes). It appears that biosynthesis of endogenous mammalian signalling molecules as well as those produced by the human microbiota may rely on the modest manipulation of primary metabolites. As a result, the structural conservation between metabolites used in host-microbial interactions and endogenous mammalian signalling metabolites may be a common phenomenon in the human microbiome. Evolutionarily, the convergence of bacterial and human signalling systems through structurally related GPCR ligands is not unreasonable as GPCRs are thought to have developed in eukaryotes to allow structurally simple signalling molecules to regulate increasingly complex cellular interactions [33] [34] [35] . The structural similarities between microbiota-encoded N-acyl amides and endogenous GPCR-active lipids may be indicative of a broader structural and functional overlap among bacterial and human bioactive lipids, including other GPCR-active N-acyl amides, eiconasoids (prostaglandins and leukotrienes) and sphingolipids. Sphingolipid-based signalling molecules may also be common in the human microbiome, because prevalent bacterial species are known to synthesize membrane sphingolipids 36 .
The GPCRs with which bacterial N-acyl amides were found to interact are all part of the same 'lipid-like' GPCR gene family. The potential importance of this GPCR family for the regulation of host-microbial interactions is suggested by their localization in areas of gastrointestinal track, which are enriched in bacteria that are predicted to synthesize GPCR ligands (Extended Data Fig. 4 ). Lipid-like GPCRs have been shown to have roles in disease models that are correlated with changes in microbial ecology, including colitis (S1PR4, PTGIR and PTGER4), obesity (GPR119), diabetes (GPR119), autoimmunity (G2A) and atherosclerosis (G2A, PTGIR) 9, 10, 13, 14 . The fact that the expression of an NAS gene in a gastrointestinal-colonizing bacterium is sufficient to alter host physiology suggests that the interaction between lipid-like GPCRs and their N-acyl amide ligands could be relevant to human physiology and warrants further study. Using LC-MS analysis, we observed most of the microbiota-encoded N-acyl amides reported here in human stool samples (Extended Data Fig. 9 ). Further studies will be needed to better define the distribution and concentration of these metabolites throughout the gastrointestinal tract, especially at the mucosa, where the physiological activity of these metabolites probably occurs. Notably, Gemella spp. predicted to encode N-acyl serinols are tightly associated with the small intestinal mucosa, supporting this site as a potentially important location for N-acyl-amide-mediated interactions 37 . Because the mouse model system used here relies on induced expression of NAS genes, it will also be important to understand how these genes are natively regulated.
Current strategies for treating diseases associated with the microbiome, such as inflammatory bowel disease or diabetes, are not believed to address the dysfunction of the host-microbial interactions that are likely to be part of the disease pathogenesis. Bacteria engineered to deliver bioactive small molecules produced by the human microbiota have the potential to help address diseases of the microbiome by modulating the native distribution and abundance of these metabolites. Regulation of GPCRs by microbiota-derived N-acyl amides is a particularly noteworthy therapeutic strategy for the treatment of human diseases, because GPCRs have been extensively validated as therapeutic targets. As our mechanistic understanding of how human microbiota-encoded small molecules effect changes in host physiology grows, the potential for using 'microbiome-biosynthetic gene therapy' to treat human disease by complementing small molecule deficiencies in native host-microbial interactions with microbiota-derived biosynthetic genes should increase accordingly. The use of functional metagenomics to identify microbiota-encoded effectors combined with bioinformatics and synthetic biology to expand effector molecule families provides a generalizable platform to help to define the role of microbiota-encoded small molecules in host-microbial interactions.
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Article reSeArcH
MethOdS Bioinformatics analysis of human N-acyl synthase genes. Protein sequences for members of the PFAM family 13444 acetyltransferase (GNAT) domain (http://pfam.xfam.org/family/PF13444) (n = 689) were downloaded and corresponding gene sequences identified based on the European Bioinformatics Institute (EBI) number. A multiple sequence alignment was performed using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/), generating a phylogenetic tree in Newick format with the '-guidetree-out' option. The 689 PFAM sequences were queried against the Human Microbiome Project (HMP) clustered gene index datasets and reference genome datasets with BLASTN (http:// hmpdacc.org/HMGC/). The PFAM13444 sequences that aligned to a HMP gene (expectation (E) < 1 × 10 −40 and > 70% identity) were identified and comprise the human microbial N-acyl synthase (hm-NAS) gene dataset (143 hm-NAS genes). Reference genomes for 111 out of 143 hm-NAS genes were identified (Supplementary Table 2 ).
To determine the abundance of hm-NAS genes within microbiomes at specific human body sites, hm-NAS genes were queried against HMP whole-metagenome shotgun-sequencing data on a per-body site basis (http://hmpdacc.org/HMASM/). Each hm-NAS gene was BLASTN searched against the non-redundant gene sets from the following body sites: buccal mucosa, anterior nares, mid vagina, posterior fornix, vaginal introitus, retroauricular crease (combined left and right), stool, supragingival plaque and tongue dorsum. These body sites were chosen, because they contained sequence data from the largest number of unique patients 38 . hm-NAS genes and highly similar genes in the HMP non-redundant gene set (E < 1 × 10 −40 ) were aligned to shotgun-sequencing reads from each patient sample taken from different sites in the human microbiome. Aligned reads were normalized to hm-NAS gene length and sequencing depth of each dataset. The normalized count of the reads aligned to each hm-NAS gene or its highly similar gene from the HMP non-redundant gene set were scaled (0-1) and colour coded per body site, and added as concentric rings around the phylogenetic tree (Fig. 1a) .
To determine the variability and distribution of hm-NAS genes that correspond to specific N-acyl amide families 1-6 ( Fig. 1) in the human microbiome, normalized read counts for each hm-NAS gene from each N-acyl amide family were plotted separately per body site as RPKM (Fig. 1c ). The tree in Fig. 1 was plotted using graphlan (https://huttenhower.sph.harvard.edu/graphlan). Analysis of metatranscriptome datasets. Two RNA-seq datasets were identified with multiple patient samples taken from separate sites in the human microbiome 39,40 . One RNA-seq dataset was part of the HMP (http://hmpdacc. org/RSEQ/) and generated from supragingival samples taken from twin pairs with and without dental caries. The second RNA-seq dataset was generated from stool samples and compared different RNA extraction methods. We used only samples labelled 'whole' , which functioned as controls for the original study 39 . Alignment of all hm-NAS genes to each dataset only identified hm-NAS genes from N-acyl amide family 1 and 2 in each of the RNA-seq datasets (1 in stool, 2 in supragingival plaque). To explore whether hm-NAS gene expression might vary between patient samples, we performed two different analyses. In the first analysis we identified reference genomes containing hm-NAS genes identical to those we used in hetero logous expression experiments for molecule families 1 and 2 (Bacteroides dorei for compound 1, Capnocytophaga ochracea for compound 2). RNA-seq reads were aligned to all of the genes from each reference genome. For each genome the average per gene read density normalized for gene length was compared to the read density seen for the hm-NAS gene. The percentile of the normalized expression of each hm-NAS gene was then plotted (0 for not expressed, 1 for the most expressed) and compared between patient samples for each RNA-seq dataset (Fig. 2a ). In the second analysis, the direct correlation between DNA and RNA abundance was determined for the stool metatranscriptome dataset for which DNA reads were also available 39 . RNA-seq and shotgun-sequenced DNA reads were aligned to the 15 hm-NAS genes from N-acyl amide family 1 that encodes N-acyl glycines (Supplementary Table 1 ). The reads were normalized (RPKM) and each hm-NAS gene from each patient sample was plotted as a single point with DNA and RNA read counts on the x and y axis, respectively (Fig. 2b ). Heterologous expression of PFAM13444 genes in E. coli. The 44 hm-NAS genes that we examined by heterologous expression were codon optimized, appended with NcoI and NdeI sites at the N and C terminus, respectively, and synthesized by Gen9. Genes obtained from Gen9 were digested with NdeI and NcoI and ligated into the corresponding restriction sites into a pET28c vector (Novagen). For heterologous expression purposes the resulting constructs were transformed into E. coli EC100 containing the T7 polymerase gene integrated into its genome (E. coli EC100:DE3). E. coli EC100:DE3 hm-NAS-containing strains were inoculated into 10 ml of Luria-Bertani (LB) broth supplemented with kanamycin (50 μ g ml −1 ) and grown overnight (37 °C with shaking 200 r.p.m.). The next day, 1 ml of overnight culture was used to inoculate 50 ml of LB broth supplemented with kanamycin (50 μ g ml −1 ) and isopropyl β -d-1-thiogalactopyranoside (IPTG) (25 μ M). Cultures were incubated at 30 °C for four days with shaking (200 r.p.m.). Each culture broth was extracted with an equal volume of ethyl acetate and the resulting extracts were dried in vacuo. Crude extracts were resuspended in 50 μ l of methanol and analysed by reversed phase HPLC-MS (XBridge Tm C 18 4.6 mm × 150 mm) using a binary solvent system (A/B solvent of water/acetonitrile with 0.1% formic acid:10% B isocratic for 5 min, gradient 10% to 100% B over 25 min). Clone-specific metabolites encoded by each hm-NAS gene were identified by comparing experimental extracts with extracts prepared from cultures of E. coli EC100:DE3 transformed with an empty pET28c vector. N-acyl amide isolation and structure determination. For each group of clones that, based on LC-MS analysis, were predicted to produce a different N-acyl amide family, we chose one representative clone for use in molecule isolation studies. Each representative clone was grown in 1.5 l of LB broth in a 2.7-l Fernach flask (30 °C, 200 r.p.m.). After four days, cultures were extracted twice with an equal volume of ethyl acetate. Dried ethyl acetate extracts were partitioned by reversedphase flash chromatography (Teledyne Isco, C 18 RediSep RF Gold 15 g), using the following mobile phase conditions: water:acetonitrile with 0.1% formic acid, 10% acetonitrile isocratic for 5 min, gradient to 100% acetonitrile over 20 min (30 ml per minute). Fractions containing clone-specific metabolites were pooled and semi-preparative reversed-phase HPLC was used to separate individual N-acyl amide molecules (Supplementary Information). The structures of compounds 2-6 were determined using a combination of HRMS, 1 H, 13 C and 2D NMR data (Supplementary Information). Compound 1 was described in our previous study 3 .
hm-NAS gene-containing bacterial species culture broth analysis.
Capnocytophaga ochracea F0287 (compound 2), Klebsiella pneumoniae WGLW1-5 (compound 3), Neisseria flavescens SK114 (compounds 4a and 4b) , and Gemella haemolysans M341 (compound 6) were obtained from the Biodefense and Emerging Infections Research Resources Repository (BEI Resources) HMP catalogue. Compound 1 was previously identified in culture broth extracts from cultures of Bacteroides vulgatus 3 . Each chosen bacteria strain contained an hm-NAS gene related to one which was heterologously expressed to produce compound 2, 3, 4a, 4b or 6. Strains were inoculated under sterile conditions into 2 l of LYBHI medium (brain-heart infusion medium supplemented with 0.5% yeast extract (Difco), 5 mg l −1 hemin (Sigma-Aldrich), 1 mg ml −1 cellobiose (Sigma-Aldrich), 1 mg ml −1 maltose (Sigma-Aldrich), 0.5 mg ml −1 cysteine (Sigma-Aldrich)) and grown anaerobically (C. ochracea) or aerobically (N. flavescens, G. haemolysans and K. pneumoniae) for seven days. Culture broths were extracted with an equal volume of ethyl acetate. To look for the presence of N-acyl amides, these extracts were examined by HPLC-MS as was described for the original heterologous expression experiments. With the exception of family 3, the N-acyl metabolite that was heterologously expressed could be identified in the culture broth extracts from the bacteria that contained that hm-NAS gene (Extended Data Fig. 1 ). GPCR screen of N-acyl amide small molecules. For each of the six N-acyl amide families (1-6), the analogue produced at the highest level in our heterologous expression experiments was assayed for GCPR activity. In the case of family 4, the major lysine analogue (N-3-hydroxyoleoyl lysine) was also screened. For family 1, the major glycine analogue (N-3-hydroxypalmitoyl glycine) was previously screened 3 . Using β -arrestin cell-based assays at 10 μ M ligand concentration, agonist and antagonist activity was assessed by DiscoveRx Corporation against 168 GPCRs with known ligands as well as 72 orphan GPCRs. The most potent interactions between N-acyl amides and GPCRs were validated by repeating the assay in duplicate and generating dose-response curves. Synthetic N-acyl amides were assayed in the same way. HEK293 cells expressing GPR119 were exposed to equimolar concentrations of N-palmitoyl serinol or OEA. cAMP concentration was used as an orthogonal assay to measure GPR119 activation. cAMP was measured in HEK293 cells engineered to express a cAMP-sensitive ion channel that permits cAMP measurement in live cells by monitoring calcium efflux (ACTOne cells, Codex Biosolutions) 41 . Calcium efflux was measured using the ACTone membrane potential kit (Codex Biosolutions CB-80500-201). For our analysis, ACTOne HEK293 cells transfected with GPR119 (ACTOne-GCPR119) were compared with cells not transfected with GPR119. Each cell line was exposed to equimolar concentrations of OEA, N-oleoyl serinol or DCEA (5-(N-ethylcarboxamido)adenosine), which stimulates GPCR ADORA2B in the parental HEK293 cell line. For a reference to the quality control of each GPCR reporter cell line from DiscoveRx, please refer to https://www.discoverx.com/targets/cell-based-assay-list?class= gpcr&pcat= stable% 20cell%20lines&readout= arrestin or Codex Biosolutions http://codexbiosolutions. com/actone_cell_lines.php.
Synthesis of proteinogenic amino-acid-containing N-acyl-palmitoyl analogues.
Wang resins with preloaded amino acids were purchased from Matrix Innovation. Coupling reagents (PyBOP and Cl − HOBt) were purchased from P3 BioSystems. Palmitoyl chloride and all other reagents were purchased from Sigma-Aldrich. Dimethylformamide (DMF) was added to preloaded Wang resins (~ 80 mg) and incubated for 30 min. Removal of N-Fmoc from swollen resins was accomplished by two rounds of piperidine treatment (20% solution in DMF (v/v), 3 ml) for 3 and 10 min, followed by several washes with DMF. Palmitoyl chloride (1 equivalent) in DMF was then added and the resin suspension was shaken for 2 h at room temperature. The N-acylated amino acid product was cleaved from the resins by treatment with trifluoroacetic acid (TFA) supplemented with 2.5% (v/v) water and 2.5% (v/v) triisopropylsilane (TIPS). After evaporation of TFA, the crude product was purified by automated reversed-phase flash chromatography (Teledyne Isco, C 18 RediSep RF Gold 15 g), binary solvent system: water and acetonitrile supplemented with 0.1% acetic acid. All final products were verified by mass spectrometry (Supplementary Table 3 ). In vitro study of GLP-1 release from GLUTag cells. OEA and 2-OG were purchased from Cayman Chemical Company and resuspended in DMSO to a concentration of 10 mM. N-oleoyl serinol was isolated and purified in the same manner as N-palmitoyl serinol described above and its identity was confirmed by 1 H NMR and HRMS. N-oleoyl serinol was resuspended at a concentration of 10 mM in DMSO. GLUTag cells were obtained from the Mangelsdorf Laboratory (University of Texas Southwestern) with permission from D. Drucker (Mount Sinai Hospital Toronto). Cells were not tested for mycoplasma or validated as they came from the group who generated the cell line. GLUTag cells were grown in DMEM, low glucose, GlutaMAX (ThermoFisher) supplemented with 10% FBS and 1% penicillin-streptomycin. After the cells reached 80% confluency, they were collected and plated 1:1 into 24-well culture plates in fresh culture medium at 50,000 cells per well. After overnight growth in culture plates, cells were washed twice with Krebs buffer supplemented with 20 μ l per ml DPP4 inhibitor (Millipore). GLUTag cells were incubated for 30 min in supplemented Krebs buffer and compounds were added at 1 μ M and 100 μ M. Cells were incubated with compounds for 2 h. Medium was then collected, centrifuged at 500g (4 °C) for 5 min and the cell-free supernatant was analysed for GLP-1 levels using the Active GLP-1 V2 kit (Mesoscale Discovery). Data from two independent experiments were analysed together for Fig. 5c (n = 6 wells for OEA, N-oleoyl serinol and n = 4 wells for 2-OG and DMSO). Colonization of germ-free and antibiotic-treated mice with N-acyl serinolproducing E. coli. All experimental procedures were approved by the Animal Care and Use Committee of The Rockefeller University. Germ-free C57BL/6 mice were maintained in sterile isolators with autoclaved food and water in the Gnotobiotic Facility of the Mucida Laboratory at The Rockefeller University. Wild-type C57BL/6 mice were purchased from Jackson Laboratory. Eight-week-old mice were used for all experiments. For colonization studies, 5 ml of an overnight culture (LB with 50 μ g ml −1 kanamycin) of E. coli transformed with pET28c:hm-NAS N-acyl serinol synthase (treatment group) or E. coli transformed with the empty pET28c vector (control group) was centrifuged at 500g for 2 min, the supernatant was decanted and the cells were resuspended in 2 ml of sterile PBS. Germ-free mice were gavaged with 100 μ l of bacterial culture immediately upon removal from sterile isolators. Antibiotic-treated mice were given water supplemented with 500 μ g ml −1 ampicillin for one week followed by gavage with E. coli clones. Suppression of endogenous microbiota was confirmed before gavage by culturing stool on non-selective LB agar and demonstrating no colony formation. After colonization, mice were housed in specific-pathogen-free conditions and fed autoclaved water and food. Water was supplemented with 35 μ g ml −1 kanamycin and 25 mM IPTG 32 . Faecal pellets from mice were analysed each week for three weeks to confirm colonization by the appropriate bacteria and to check for contamination by plating on LB agar with and without 50 μ g ml −1 kanamycin (Extended Data Fig. 7) . A single fresh mouse faecal pellet was weighed and resuspended in PBS at a fixed concentration (400 μ l per 40 mg). Subsequently, 1 μ l of this suspension was diluted 1:100 in PBS and plated in duplicate. The average number of colonies per plate (two plates) was recorded. Plasmids were isolated and restriction mapped from these colonies to confirm the presence of the correct hm-NAS gene insert or lack thereof. Ethyl acetate extracts from broth cultures were also examined as previously discussed to confirm the production of N-acyl serinols by bacteria in the treatment group. In the first experiment of germ-free mice, seven mice were studied-3 (one male, two females) in the treatment group and four (two males, two females) in the control group. The independent replicate experiment of germ-free mice also consisted of seven mice (all female, three in the treatment group and four in the control group). Mice were all individually caged and at the end of each week, food consumption and weight were measured. In the antibiotic-treated mouse cohort 18 mice were studied (two independent experiments of nine male mice in the treatment group and nine male mice in the control group). Mice were of the same size and gender distribution in each replicate. In the antibiotic-treated study, the control mouse group was treated with E. coli transformed with pET28c:hm-NAS, which contains an N-acyl serinol synthase gene containing a single point mutation that rendered the enzyme non-functional (E91A) (see below). The animal experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. No statistical methods were used to predetermine sample size. Data for all mice that completed the experiments were analysed.
Generation of an active-site pET28c:hm-NAS N-acyl serinol synthase mutant. Conserved active site residues in bacterial NAS genes were identified in previous biochemical and X-ray crystallography studies 42 . To create a catalyti cally inactive N-acyl serinol synthase, we changed a key glutamic acid residue (Glu91) to alanine. The point mutation was created by PCR using a pET28c:hm-NAS N-acyl serinol synthase vector as template and the following primers forward: GTTCTGTGCGATACGTCTCC; and reverse: GCCTTTCACAGGCAGATATTC. The position of the point mutation is underlined in the forward primer. The resulting PCR reaction was digested with DpnI to remove any remaining methylated vector. The PCR product was then phosphorylated, column purified and blunt end ligated (End-It, Epicentre). The vector was transformed into EC100:DE3 cells and the point mutation was confirmed by Sanger sequencing. When transformed into E. coli, the resultant E91A mutant construct did not confer the production of any detectable N-acyl serinols. Cultures were grown under the same conditions as the original N-acyl serinol synthase producing clone (Extended Data Fig. 8) . Oral glucose tolerance test. One week after colonization, mice were fasted overnight (16 h) and then administered a 2 g kg −1 OGTT (40% glucose solution). Blood glucose was measured by tail bleed (Breeze 2 Bayer) at time 0, before the glucose gavage, then 15, 30, 60, 90 and 120 min after gavage. After one week, the IPTG was removed from the drinking water and mice were allowed to equilibrate for an additional two weeks 32 . Three weeks after colonization the OGTT was repeated. Blood glucose levels at each time point during the OGTT tests were compared between groups using a Student's t-test with a significance threshold of P < 0.05. Insulin and GLP-1 measurement. Mice were given an OGTT as previously described. At 15 min, blood was collected by submandibular bleed and immediately mixed with 10 μ l of 0.5 M EDTA and 5 μ l of DPPIV inhibitor (Millipore, DPP4-010) per 500 μ l of blood. Treated blood was spun at 2,000g for 15 min at 4 °C. Plasma was collected and immediately placed at − 80 °C. Insulin was measured using the Crystal Chem Ultra Sensitive Mouse ELISA kit and active GLP-1 was measured using the Mesoscale Discovery Active GLP-1 V2 kit. Samples were analysed for insulin in triplicate and GLP-1 in duplicate. Insulin was measured from mice in one experiment (n = 6 mice in each group). GLP-1 was measured from mice in two independent experiments (n = 9 mice in the control, n = 10 mice in the treatment group). All mice were male and of the same size distribution. N-acyl serinol metabolite measurement in mouse caecal samples and human stool. After withholding IPTG for two weeks, mice from the first experimental set were re-exposed to IPTG in the drinking water for one week to induce hm-NAS gene expression and N-acyl serinol production. Mice were euthanized and caecal samples taken. Fresh caecal stool from two control mice and two treated mice was resuspended in 5 ml of sterile PBS and extracted 1:1 with ethyl acetate. Crude extracts were dried in vacuo and resuspended in methanol normalized by crude extract weight. Each extract was then analysed by reversed-phase liquid chromatography coupled to a 6550 Q-TOF mass spectrometer (Agilent Technologies). Peak identities were confirmed by accurate mass, and also by comparison of chromatographic retention time and MS/MS spectra to those of the purified N-palmitoyl serinol standard. For both mice in the treatment group, N-palmitoyl serinol could be detected in the caecal samples, whereas N-palmitoyl serinol was detected in neither of the mice in the control group (Extended Data Fig. 6 ). Stool samples were collected from human subjects before bone marrow transplant as part of a previous clinical trial conducted at Memorial Sloan Kettering in collaboration with J.C. Fresh stool samples were processed in the same way as the mouse caecal samples described above. Data availability. All figure data are available as Source Data. Gene accession numbers for all cloned genes are provided in Supplementary Table 1 . Publically available DNA and RNA datasets that were analysed in this study are referenced accordingly and references contain links to datasets that are available for downloading. Corresponding author(s): Sean Brady
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